The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The pharmaceutical sector showed mixed results as Merck & Co's sales growth was driven by its blockbuster drug Keytruda, leading the company to tighten its 2026 sales outlook. Meanwhile, Bristol Myers Squibb beat estimates on the back of its new portfolio, and Moderna reported an increase in first-quarter revenue driven by international Covid-19 vaccine sales, despite reporting a net financial loss. In the industrial sector, Trane Technologies reported record bookings of $10.7 billion, representing a 24% year-over-year increase. Due to this robust demand, Trane raised its financial guidance for 2026. These updates highlight sustained commercial momentum across both healthcare and climate innovation sectors. Analysts suggest that the underlying operational strength and record backlogs support a positive long-term trajectory for these industry leaders.
Sign in to access this content
Sign In